{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:45:32Z","timestamp":1785775532889,"version":"3.56.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jctube.2026.100607","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:56:12Z","timestamp":1777046172000},"page":"100607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapeutic drug monitoring of first-line anti-tuberculosis drugs: impact of dose modification on plasma drug concentrations in pulmonary and extrapulmonary tuberculosis"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1710-6787","authenticated-orcid":false,"given":"Aishwarya","family":"Alavandar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jctube.2026.100607_b0005","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.jctube.2026.100607_b0010","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1128\/AAC.00461-07","article-title":"Variability in the population pharmacokinetics of rifampicin in tuberculosis patients","volume":"52","author":"Wilkins","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jctube.2026.100607_b0015","unstructured":"Akkerman OW, Alffenaar J-WC, Bolhuis MS, et al. Therapeutic drug monitoring in tuberculosis treatment: a systematic review. Eur Respir J. 2019;53(4):1802016. doi:10.1183\/13993003.02016-2018."},{"issue":"7","key":"10.1016\/j.jctube.2026.100607_b0020","first-page":"1127","article-title":"Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes","volume":"200","author":"Chideya","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jctube.2026.100607_b0025","first-page":"2133","article-title":"Population pharmacokinetics of rifampicin","volume":"52","author":"Wilkins","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jctube.2026.100607_b0030","first-page":"701","article-title":"Determinants of rifampicin and isoniazid pharmacokinetics","volume":"56","author":"McIlleron","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jctube.2026.100607_b0035","first-page":"37","article-title":"Concentration-dependent killing and resistance prevention by rifampin","volume":"82","author":"Gumbo","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jctube.2026.100607_b0040","first-page":"235","article-title":"NAT2 genotyping and isoniazid pharmacokinetics","volume":"77","author":"Kinzig-Schippers","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jctube.2026.100607_b0045","first-page":"160","article-title":"NAT2 genotype-guided regimen in tuberculosis","volume":"381","author":"Azuma","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jctube.2026.100607_b0050","first-page":"701","article-title":"Determinants of first-line anti-TB drug exposure","volume":"56","author":"McIlleron","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jctube.2026.100607_b0055","first-page":"100","article-title":"Pharmacokinetics of first-line anti-tuberculosis drugs in children","volume":"20","author":"Ramachandran","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jctube.2026.100607_b0060","first-page":"143","article-title":"Serum concentrations and TB outcomes","volume":"94","author":"Pasipanodya","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jctube.2026.100607_b0065","first-page":"74","article-title":"PK variability and multidrug-resistant tuberculosis","volume":"108","author":"Srivastava","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jctube.2026.100607_b0070","first-page":"37","article-title":"Rifampin exposure and resistance suppression","volume":"82","author":"Gumbo","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.jctube.2026.100607_b0075","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in tuberculosis","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jctube.2026.100607_b0080","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/cid\/ciw677","article-title":"Practical application of therapeutic drug monitoring in tuberculosis","volume":"64","author":"Alffenaar","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jctube.2026.100607_b0085","first-page":"1417","article-title":"Therapeutic drug monitoring for slow TB response","volume":"71","author":"Heysell","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jctube.2026.100607_b0090","series-title":"Technical Report on Critical Concentrations and Pharmacokinetics of Anti-Tuberculosis Drugs","author":"World Health Organization","year":"2018"}],"container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240557942600029X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240557942600029X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:55:30Z","timestamp":1785772530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240557942600029X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":18,"alternative-id":["S240557942600029X"],"URL":"https:\/\/doi.org\/10.1016\/j.jctube.2026.100607","relation":{},"ISSN":["2405-5794"],"issn-type":[{"value":"2405-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic drug monitoring of first-line anti-tuberculosis drugs: impact of dose modification on plasma drug concentrations in pulmonary and extrapulmonary tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jctube.2026.100607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100607"}}